TACE联合抗病毒治疗HBV相关性肝癌的预后观察及相关因素分析

摘要 目的：分析影响肝动脉化疗栓塞（TACE）联合抗病毒治疗乙型肝炎病毒（HBV）相关性肝癌预后的相关因素。方法：纳入的130例HBV相关性肝癌选自于本院2018年2月至2020年3月期间所收治,所有患者均行TACE联合抗病毒治疗,记录其生存情况,并对影响患者预后的相关因素进行分析与探讨。结果：130例患者随访截止时,死亡58例,存活72例,中位生存期为24个月,1年生存率为82.31%,2年生存率为55.38%;单因素及多因素Cox回归分析结果显示,肿瘤最大直径、血清AFP、Child-Pugh分级、腹腔转移、门静脉癌栓是患者预后不良的的危险因素。结论：肿瘤最大直径、血清AFP、Child-Pugh分级、腹腔转移、门静脉癌栓是影响TACE联合抗病毒治疗HBV相关性肝癌病患预后的影响因素。

Prognostic Factors of TACE Combined with Antiviral Therapy for HBV-associated Hepatocellular Carcinoma

ABSTRACT Objective: To analyze the prognostic factors of transarterial chemoembolization (TACE) combined with antiviral therapy for hepatitis B virus (HBV)-associated hepatocellular carcinoma. Methods: This study included 130 patients with HBV-associated hepatocellular carcinoma admitted to the hospital from February 2018 to March 2020. All patients underwent TACE combined with antiviral therapy, and their survival status was recorded. The prognostic factors were analyzed. Results: At the end of follow-up, 58 patients died and 72 patients survived, with a median survival time of 24 months. The 1-year and 2-year survival rates were 82.31% and 55.38%. Univariate analysis and multivariate Cox regression analysis found that the maximum tumor diameter, serum AFP, Child-Pugh grade, abdominal cavity metastasis, and portal vein tumor thrombus were risk factors for poor prognosis. Conclusion: The maximum tumor diameter, serum AFP, Child-Pugh grade, abdominal cavity metastasis, and portal vein tumor thrombus are factors affecting the prognosis of HBV-associated hepatocellular carcinoma treated with TACE combined with antiviral therapy.